The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
The Diagnosis and Treatment of Prostate Cancer: A Review
Abstract
IMPORTANCE: Prostate cancer is the most common cancer diagnosis made in men with more than 160 000 new cases each year in the United States. Although it often has an indolent course, prostate cancer remains the third-leading cause of cancer death in men. OBSERVATIONS: When prostate cancer is suspected, tissue biopsy remains the standard of care for diagnosis. However, the identification and characterization of the disease have become increasingly precise through improved risk stratification and advances in magnetic resonance and functional imaging, as well as from the emergence of biomarkers. Multiple management options now exist for men diagnosed with prostate cancer. Active surveillance (the serial monitoring for disease progression with the intent to cure) appears to be safe and has become the preferred approach for men with less-aggressive prostate cancer, particularly those with a prostate-specific antigen level of less than 10 ng/mL and Gleason score 3 + 3 tumors. Surgery and radiation continue to be curative treatments for localized disease but have adverse effects such as urinary symptoms and sexual dysfunction that can negatively affect quality of life. For metastatic disease, chemotherapy as initial treatment now appears to extend survival compared with androgen deprivation therapy alone. New vaccines, hormonal therapeutics, and bone-targeting agents have demonstrated efficacy in men with metastatic prostate cancer resistant to traditional hormonal therapy. CONCLUSIONS AND RELEVANCE: Advances in the diagnosis and treatment of prostate cancer have improved the ability to stratify patients by risk and allowed clinicians to recommend therapy based on cancer prognosis and patient preference. Initial treatment with chemotherapy can improve survival compared with androgen deprivation therapy. Abiraterone, enzalutamide, and other agents can improve outcomes in men with metastatic prostate cancer resistant to traditional hormonal therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Cancer treatment and survivorship statistics, 2016
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408
de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
Epstein, J. I., Egevad, L., Amin, M. B., Delahunt, B., Srigley, J. R., & Humphrey, P. A. (2016) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000530 · Cited by 3,236
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028
PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2
Weinreb, J. C., Barentsz, J. O., Choyke, P. L., Cornud, F., Haider, M. A., Macura, K. J., Margolis, D., Schnall, M. D., Shtern, F., Tempany, C. M., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.08.052 · Cited by 2,951
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Sweeney, C. J., Chen, Y.-H., Carducci, M., Liu, G., Jarrard, D. F., Eisenberger, M., Wong, Y.-N., Hahn, N., Kohli, M., Cooney, M. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503747 · Cited by 2,896
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer
Hamdy, F. C., Donovan, J. L., Lane, J. A., Mason, M., Metcalfe, C., Holding, P., Davis, M., Peters, T. J., Turner, E. L., Martin, R. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606220 · Cited by 2,640
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185
James, N. D., Sydes, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Spears, M. R., Ritchie, A. W. S., Parker, C. C., Russell, J. M., Attard, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01037-5 · Cited by 1,978
Fizazi, K., Carducci, M., Smith, M., Damião, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62344-6 · Cited by 1,971
Radical Prostatectomy versus Observation for Localized Prostate Cancer
Wilt, T. J., Brawer, M. K., Jones, K. M., Barry, M. J., Aronson, W. J., Fox, S., Gingrich, J. R., Wei, J. T., Gilhooly, P., Grob, B. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113162 · Cited by 1,770
Siddiqui, M. M., Rais-Bahrami, S., Turkbey, B., George, A. K., Rothwax, J., Shakir, N., Okoro, C., Raskolnikov, D., Parnes, H. L., Linehan, W. M., et al. (2015) · JAMA · doi:10.1001/jama.2014.17942 · Cited by 1,505
A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score
Epstein, J. I., Zelefsky, M. J., Sjoberg, D. D., Nelson, J. B., Egevad, L., Magi-Galluzzi, C., Vickers, A. J., Parwani, A. V., Reuter, V. E., Fine, S. W., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.06.046 · Cited by 1,374
Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer
Donovan, J. L., Hamdy, F. C., Lane, J. A., Mason, M., Metcalfe, C., Walsh, E., Blazeby, J. M., Peters, T. J., Holding, P., Bonnington, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606221 · Cited by 1,338
Ficarra, V., Novara, G., Rosen, R. C., Artibani, W., Carroll, P. R., Costello, A., Menon, M., Montorsi, F., Patel, V. R., Stolzenburg, J.-U., et al. (2012) · European Urology · doi:10.1016/j.eururo.2012.05.045 · Cited by 1,300
Early Detection of Prostate Cancer: AUA Guideline
Carter, H. B., Albertsen, P. C., Barry, M. J., Etzioni, R., Freedland, S. J., Greene, K. L., Holmberg, L., Kantoff, P., Konety, B. R., Murad, M. H., et al. (2013) · Journal of Urology · doi:10.1016/j.juro.2013.04.119 · Cited by 1,242
Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer
Klotz, L., Vesprini, D., Sethukavalan, P., Jethava, V., Zhang, L., Jain, S., Yamamoto, T., Mamedov, A., & Loblaw, A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.1192 · Cited by 1,221
Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer
Bill-Axelson, A., Holmberg, L., Garmo, H., Rider, J. R., Taari, K., Busch, C., Nordling, S., Häggman, M., Andersson, S.-O., Spångberg, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311593 · Cited by 981
Bolla, M., van Poppel, H., Tombal, B., Vekemans, K., Da Pozzo, L., de Reijke, T. M., Verbaeys, A., Bosset, J.-F., van Velthoven, R., Colombel, M., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61253-7 · Cited by 867
Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
Nguyen, P. L., Alibhai, S. M. H., Basaria, S., D’Amico, A. V., Kantoff, P. W., Keating, N. L., Penson, D. F., Rosario, D. J., Tombal, B., & Smith, M. R. (2015) · European Urology · doi:10.1016/j.eururo.2014.07.010 · Cited by 831
Ficarra, V., Novara, G., Ahlering, T. E., Costello, A., Eastham, J. A., Graefen, M., Guazzoni, G., Menon, M., Mottrie, A., Patel, V. R., et al. (2012) · European Urology · doi:10.1016/j.eururo.2012.05.046 · Cited by 786
COOPERBERG, M. R., PASTA, D. J., ELKIN, E. P., LITWIN, M. S., LATINI, D. M., Du CHANE, J., & CARROLL, P. R. (2005) · Journal of Urology · doi:10.1097/01.ju.0000158155.33890.e7 · Cited by 772
Self-citationYaxley, J. W., Coughlin, G. D., Chambers, S. K., Occhipinti, S., Samaratunga, H., Zajdlewicz, L., Dunglison, N., Carter, R., Williams, S., Payton, D. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30592-x · Cited by 715
Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer
Shipley, W. U., Seiferheld, W., Lukka, H. R., Major, P. P., Heney, N. M., Grignon, D. J., Sartor, O., Patel, M. P., Bahary, J.-P., Zietman, A. L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607529 · Cited by 663
Klein, E. A., Cooperberg, M. R., Magi-Galluzzi, C., Simko, J. P., Falzarano, S. M., Maddala, T., Chan, J. M., Li, J., Cowan, J. E., Tsiatis, A. C., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.05.004 · Cited by 659
Prostate Cancer, Version 1.2016
Mohler, J. L., Armstrong, A. J., Bahnson, R. R., D'Amico, A. V., Davis, B. J., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., Horwitz, E. M., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0004 · Cited by 653
Stephenson, A. J., Scardino, P. T., Eastham, J. A., Bianco, F. J., Dotan, Z. A., Fearn, P. A., & Kattan, M. W. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj190 · Cited by 623
Tosoian, J. J., Mamawala, M., Epstein, J. I., Landis, P., Wolf, S., Trock, B. J., & Carter, H. B. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.5764 · Cited by 555
Hoskin, P. J., Rojas, A. M., Bownes, P. J., Lowe, G. J., Ostler, P. J., & Bryant, L. (2012) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2012.01.007 · Cited by 497
Dearnaley, D. P., Jovic, G., Syndikus, I., Khoo, V., Cowan, R. A., Graham, J. D., Aird, E. G., Bottomley, D., Huddart, R. A., Jose, C. C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70040-3 · Cited by 463
70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of GETUG 06 Randomized Trial
Beckendorf, V., Guerif, S., Le Prisé, E., Cosset, J.-M., Bougnoux, A., Chauvet, B., Salem, N., Chapet, O., Bourdain, S., Bachaud, J.-M., et al. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.03.049 · Cited by 452
Wiegel, T., Bartkowiak, D., Bottke, D., Bronner, C., Steiner, U., Siegmann, A., Golz, R., Störkel, S., Willich, N., Semjonow, A., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.03.011 · Cited by 440
Nguyen, P. L., Je, Y., Schutz, F. A. B., Hoffman, K. E., Hu, J. C., Parekh, A., Beckman, J. A., & Choueiri, T. K. (2011) · JAMA · doi:10.1001/jama.2011.1745 · Cited by 432
Stephenson, A. J., Kattan, M. W., Eastham, J. A., Bianco, F. J., Yossepowitch, O., Vickers, A. J., Klein, E. A., Wood, D. P., & Scardino, P. T. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.2501 · Cited by 419
Filson, C. P., Natarajan, S., Margolis, D. J. A., Huang, J., Lieu, P., Dorey, F. J., Reiter, R. E., & Marks, L. S. (2016) · Cancer · doi:10.1002/cncr.29874 · Cited by 406
American Cancer Society prostate cancer survivorship care guidelines
Skolarus, T. A., Wolf, A. M. D., Erb, N. L., Brooks, D. D., Rivers, B. M., Underwood, W., Salner, A. L., Zelefsky, M. J., Aragon‐Ching, J. B., Slovin, S. F., et al. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21234 · Cited by 398
Adjuvant and Salvage Radiotherapy After Prostatectomy: AUA/ASTRO Guideline
Thompson, I. M., Valicenti, R. K., Albertsen, P., Davis, B. J., Goldenberg, S. L., Hahn, C., Klein, E., Michalski, J., Roach, M., Sartor, O., et al. (2013) · Journal of Urology · doi:10.1016/j.juro.2013.05.032 · Cited by 391
Screening for Prostate Cancer With the Prostate-Specific Antigen Test: A Review of Current Evidence
Hayes, J. H., & Barry, M. J. (2014) · JAMA · doi:10.1001/jama.2014.2085 · Cited by 361
Rosenkrantz, A. B., Verma, S., Choyke, P., Eberhardt, S. C., Eggener, S. E., Gaitonde, K., Haider, M. A., Margolis, D. J., Marks, L. S., Pinto, P., et al. (2016) · Journal of Urology · doi:10.1016/j.juro.2016.06.079 · Cited by 353
Barocas, D. A., Alvarez, J., Resnick, M. J., Koyama, T., Hoffman, K. E., Tyson, M. D., Conwill, R., McCollum, D., Cooperberg, M. R., Goodman, M., et al. (2017) · JAMA · doi:10.1001/jama.2017.1704 · Cited by 344
Chen, R. C., Basak, R., Meyer, A.-M., Kuo, T.-M., Carpenter, W. R., Agans, R. P., Broughman, J. R., Reeve, B. B., Nielsen, M. E., Usinger, D. S., et al. (2017) · JAMA · doi:10.1001/jama.2017.1652 · Cited by 325
Aluwini, S., Pos, F., Schimmel, E., Krol, S., van der Toorn, P. P., de Jager, H., Alemayehu, W. G., Heemsbergen, W., Heijmen, B., & Incrocci, L. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00567-7 · Cited by 309
Zapatero, A., Guerrero, A., Maldonado, X., Alvarez, A., Segundo, C. G. S., Rodríguez, M. A. C., Macias, V., Olive, A. P., Casas, F., Boladeras, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70045-8 · Cited by 301
Exercise for men with prostate cancer: a systematic review and meta-analysis
Bourke, L., Smith, D., Steed, L., Hooper, R., Carter, A., Catto, J., Albertsen, P. C., Tombal, B., Payne, H. A., & Rosario, D. J. (2016) · European Urology · doi:10.1016/j.eururo.2015.10.047 · Cited by 300
New and Established Technology in Focal Ablation of the Prostate: A Systematic Review
Valerio, M., Cerantola, Y., Eggener, S. E., Lepor, H., Polascik, T. J., Villers, A., & Emberton, M. (2017) · European Urology · doi:10.1016/j.eururo.2016.08.044 · Cited by 300
Predicting the Presence and Side of Extracapsular Extension: A Nomogram for Staging Prostate Cancer
OHORI, M., KATTAN, M. W., KOH, H., MARU, N., SLAWIN, K. M., SHARIAT, S., MURAMOTO, M., REUTER, V. E., WHEELER, T. M., & SCARDINO, P. T. (2004) · Journal of Urology · doi:10.1097/01.ju.0000121693.05077.3d · Cited by 297
Wallis, C. J. D., Saskin, R., Choo, R., Herschorn, S., Kodama, R. T., Satkunasivam, R., Shah, P. S., Danjoux, C., & Nam, R. K. (2016) · European Urology · doi:10.1016/j.eururo.2015.11.010 · Cited by 282
Can Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer?
Wei, J. T., Feng, Z., Partin, A. W., Brown, E., Thompson, I., Sokoll, L., Chan, D. W., Lotan, Y., Kibel, A. S., Busby, J. E., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.8505 · Cited by 274
Schellhammer, P. F., Chodak, G., Whitmore, J. B., Sims, R., Frohlich, M. W., & Kantoff, P. W. (2013) · Urology · doi:10.1016/j.urology.2013.01.061 · Cited by 242
Fizazi, K., Faivre, L., Lesaunier, F., Delva, R., Gravis, G., Rolland, F., Priou, F., Ferrero, J.-M., Houede, N., Mourey, L., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00011-x · Cited by 239
Partin, A. W., Van Neste, L., Klein, E. A., Marks, L. S., Gee, J. R., Troyer, D. A., Rieger-Christ, K., Jones, J. S., Magi-Galluzzi, C., Mangold, L. A., et al. (2014) · Journal of Urology · doi:10.1016/j.juro.2014.04.013 · Cited by 226
Bolla, M., Maingon, P., Carrie, C., Villa, S., Kitsios, P., Poortmans, P. M. P., Sundar, S., van der Steen-Banasik, E. M., Armstrong, J., Bosset, J.-F., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8055 · Cited by 219
Bourke, L., Gilbert, S., Hooper, R., Steed, L. A., Joshi, M., Catto, J. W. F., Saxton, J. M., & Rosario, D. J. (2014) · European Urology · doi:10.1016/j.eururo.2013.09.040 · Cited by 205
James, N. D., Spears, M. R., Clarke, N. W., Dearnaley, D. P., Mason, M. D., Parker, C. C., Ritchie, A. W. S., Russell, J. M., Schiavone, F., Attard, G., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4350 · Cited by 188
Daskivich, T. J., Fan, K.-H., Koyama, T., Albertsen, P. C., Goodman, M., Hamilton, A. S., Hoffman, R. M., Stanford, J. L., Stroup, A. M., Litwin, M. S., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-10-201305210-00005 · Cited by 184
Self-citationYu, J. B., Cramer, L. D., Herrin, J., Soulos, P. R., Potosky, A. L., & Gross, C. P. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.8652 · Cited by 164
Godtman, R. A., Holmberg, E., Khatami, A., Pihl, C.-G., Stranne, J., & Hugosson, J. (2016) · European Urology · doi:10.1016/j.eururo.2016.03.048 · Cited by 163
Association Between Androgen Deprivation Therapy and Risk of Dementia
Nead, K. T., Gaskin, G., Chester, C., Swisher-McClure, S. D., Leeper, N. J., & Shah, N. H. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3662 · Cited by 160
Decision aids for localized prostate cancer treatment choice: Systematic review and meta‐analysis
Violette, P. D., Agoritsas, T., Alexander, P. E., Riikonen, J. M., Santti, H., Agarwal, A., Bhatnagar, N., Dahm, P., Montori, V. M., Guyatt, G. H., et al. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21272 · Cited by 148
Wilkins, A. C., Mossop, H., Syndikus, I., Khoo, V. S., Bloomfield, D. J., Parker, C. C., Logue, J. P., Scrase, C. D., Patterson, H., Birtle, A. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00280-6 · Cited by 146
Magnan, S., Zarychanski, R., Pilote, L., Bernier, L., Shemilt, M., Vigneault, É., Fradet, V., & Turgeon, A. F. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2895 · Cited by 142
D'Amico, A. V., Chen, M., Renshaw, A. A., Loffredo, M. J., & Kantoff, P. W. (2015) · JAMA · doi:10.1001/jama.2015.8577 · Cited by 139
Targeted Prostate Biopsy to Select Men for Active Surveillance: Do the Epstein Criteria Still Apply?
Hu, J. C., Chang, E., Natarajan, S., Margolis, D., Macairan, M., Lieu, P., Huang, J., Sonn, G. A., Dorey, F. J., & Marks, L. S. (2014) · The Journal of Urology · doi:10.1016/j.juro.2014.02.005 · Cited by 126
Viani, G. A., Viana, B. S., Martin, J. E. C., Rossi, B. T., Zuliani, G., & Stefano, E. J. (2016) · Cancer · doi:10.1002/cncr.29983 · Cited by 122
A Systematic Review of Hypofractionation for Primary Management of Prostate Cancer
Koontz, B. F., Bossi, A., Cozzarini, C., Wiegel, T., & D'Amico, A. V. (2014) · European Urology · doi:10.1016/j.eururo.2014.08.009 · Cited by 108
Scattoni, V., Lazzeri, M., Giovanni Lughezzani, A., LUCA, S. D., Passera, R., Bollito, E., Randone, D. F., Abdollah, F., Umberto Capitanio, A., Larcher, A., et al. (2013) · The Journal of Urology · doi:10.1016/j.juro.2013.02.3184 · Cited by 103
Sommariva, S., Tarricone, R., Lazzeri, M., Ricciardi, W., & Montorsi, F. (2014) · European Urology · doi:10.1016/j.eururo.2014.11.038 · Cited by 92
Expectant management for men with early stage prostate cancer
Filson, C. P., Marks, L. S., & Litwin, M. S. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21278 · Cited by 83
Self-citationWootten, A. C., Abbott, J.-A. M., Meyer, D., Chisholm, K., Austin, D. W., Klein, B., McCabe, M., Murphy, D. G., & Costello, A. J. (2015) · European Urology · doi:10.1016/j.eururo.2014.10.024 · Cited by 77
Knudsen, B. S., Kim, H. L., Erho, N., Shin, H., Alshalalfa, M., Lam, L. L. C., Tenggara, I., Chadwich, K., van der Kwast, T., Fleshner, N. E., et al. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.12.006 · Cited by 61
Stefanopoulou, E., Yousaf, O., Grunfeld, E. A., & Hunter, M. S. (2015) · Psycho-Oncology · doi:10.1002/pon.3794 · Cited by 49
Siddons, H. M., Wootten, A. C., & Costello, A. J. (2013) · Psycho-Oncology · doi:10.1002/pon.3273 · Cited by 48
Couper, J. W., Collins, A., Bloch, S., Street, A. F., Duchesne, G. M., Jones, T. M., Olver, J. S., & Love, A. W. (2015) · British Journal of Urology · doi:10.1111/bju.12991 · Cited by 48
Zhang, A. Y., Bodner, D. R., Fu, A. Z., Gunzler, D. D., Klein, E. A., Kresevic, D. M., Moore, S. M., Ponsky, L. E., Purdum, M., Strauss, G. J., et al. (2015) · The Journal of Urology · doi:10.1016/j.juro.2015.07.090 · Cited by 38
PATEL, H. R. H., Ilo, D., Shah, N. C., Cuzin, B., Chadwick, D., Andrianne, R., Henneges, C., Barry, J., Hell-Momeni, K., Branicka, J., et al. (2015) · BMC Urology · doi:10.1186/s12894-015-0022-9 · Cited by 27
Evaluating an Elevated Screening PSA Test
Barry, M. J., & Hayes, J. H. (2015) · JAMA · doi:10.1001/jama.2015.12614 · Cited by 6
Cited by
Genetics and biology of prostate cancer
Wang, G., Zhao, D., Spring, D. J., & DePinho, R. A. (2018) · Genes & Development · doi:10.1101/gad.315739.118 · Cited by 750
Kloss, C. C., Lee, J., Zhang, A., Chen, F., Melenhorst, J. J., Lacey, S. F., Maus, M. V., Fraietta, J. A., Zhao, Y., & June, C. H. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.003 · Cited by 648
Genomic and phenotypic heterogeneity in prostate cancer
Haffner, M. C., Zwart, W., Roudier, M. P., True, L. D., Nelson, W. G., Epstein, J. I., De Marzo, A. M., Nelson, P. S., & Yegnasubramanian, S. (2021) · Nature Reviews Urology · doi:10.1038/s41585-020-00400-w · Cited by 502
Roles and mechanisms of exosomal non-coding RNAs in human health and diseases
Li, C., Ni, Y.-Q., Xu, H., Xiang, Q.-Y., Zhao, Y., Zhan, J.-K., He, J.-Y., Li, S., & Liu, Y.-S. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00779-x · Cited by 406
Han, X., Wang, C., Qin, C., Xiang, W., Fernandez-Salas, E., Yang, C.-Y., Wang, M., Zhao, L., Xu, T., Chinnaswamy, K., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01631 · Cited by 381
Metadata
- Authors
- Litwin, M. S., & Tan, H.-J.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2017-06-27
- Volume
- 317
- Issue
- 24
- Pages
- 2532
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2727380696
- Cited by
- 1,435
- References
- 84
- FWCI
- 67.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.